tirzepatide patent expiry in india Drug Patents containing India's weight-loss drug rush kicks
Description
In this story we will cover one small aspect of the 2025 USRDS report: the change in incidence of ESRD over time
Tirzepatide does not have this direct hepatic mechanism
They projected that based on the known weight-loss and cardiovascular risk factor effects of this therapy that its use could result in 55 million fewer people with obesity and prevent up to 2 million heart attacks, strokes and other adverse cardiovascular events over 10 years
Afternoon snack: Cottage cheese (1/2 cup) with walnuts (7 halves)
